PHASE 3 RANDOMIZED TRIAL OF MOMELOTINIB VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH MYELOFIBROSIS PREVIOUSLY TREATED WITH RUXOLITINIB: RESULTS OF THE SIMPLIFY-2 STUDY

被引：0

作者：

Verstovsek, S. ^{[1
]}

Vannucchi, A. M. ^{[2
]}

Platzbecker, U. ^{[3
]}

Cervantes, F. ^{[4
]}

Gupta, V. ^{[5
]}

Lavie, D. ^{[6
]}

Passamonti, F. ^{[7
]}

Winton, E. F. ^{[8
]}

Dong, H. ^{[9
]}

Kawashima, J. ^{[9
]}

Maltzman, J. D. ^{[9
]}

Kiladjian, J-J. ^{[10
,11
]}

Harrison, C. N. ^{[12
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Univ Florence, Florence, Italy

[3] Tech Univ, Med Fak Carl Gustav Carus, Dresden, Germany

[4] Univ Barcelona, Hosp Clin, Barcelona, Spain

[5] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada

[6] Hadassah Hebrew Univ Med Ctr, Jerusalem, Israel

[7] Univ Insubria, Varese, Italy

[8] Emory Univ, Sch Med, Atlanta, GA USA

[9] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA

[10] St Louis Hosp, AP HP, Paris, France

[11] Paris Diderot Univ, Paris, France

[12] Guys & St Thomas NHS Fdn Trust, London, England

来源：

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

S786

引用

页码：320 / 321

页数：2